|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9431
|
|
pubmed:dateCreated |
2004-7-27
|
|
pubmed:abstractText |
Endothelin-receptor blockade provides haemodynamic benefit in experimental and clinical heart failure. We aimed to measure the effects of long-term endothelin-blockade on left-ventricular (LV) remodelling and clinical outcomes in patients with chronic heart failure.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
364
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
347-54
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15276394-Dose-Response Relationship, Drug,
pubmed-meshheading:15276394-Double-Blind Method,
pubmed-meshheading:15276394-Endothelin-1,
pubmed-meshheading:15276394-Female,
pubmed-meshheading:15276394-Heart Failure,
pubmed-meshheading:15276394-Humans,
pubmed-meshheading:15276394-Male,
pubmed-meshheading:15276394-Middle Aged,
pubmed-meshheading:15276394-Phenylpropionates,
pubmed-meshheading:15276394-Pyrimidines,
pubmed-meshheading:15276394-Receptor, Endothelin A,
pubmed-meshheading:15276394-Stroke Volume,
pubmed-meshheading:15276394-Treatment Outcome,
pubmed-meshheading:15276394-Ventricular Remodeling
|
|
pubmed:articleTitle |
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
